Is it possible to have a combination of primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis?

Yes, overlap syndromes combining features of PBC, PSC, and autoimmune hepatitis are possible, though extremely rare.

Overlap syndromes represent phenotypic variations along a continuous spectrum of autoimmune liver disease rather than distinct entities, and patients can present with features of two or even three conditions simultaneously or sequentially. 1

Understanding Overlap Syndromes

AIH-PBC Overlap Syndrome

This is the most common overlap pattern, occurring in 8-10% of AIH patients 2. Key diagnostic features include:

• Moderate to severe interface hepatitis on liver biopsy (prerequisite for diagnosis) 1
• Cholestatic features: elevated alkaline phosphatase, pruritus, cholestatic liver biochemistry
• Positive antimitochondrial antibodies (AMA) - though AMA positivity alone (8-12% of AIH patients) without bile duct damage does NOT constitute overlap syndrome 2
• Can present simultaneously (7.8% of cases) or sequentially - AIH first (1.8%) or PBC first (4.3%) 2

AIH-PSC Overlap Syndrome

Less common, reported in 6-11% of AIH patients in Western populations but very rare in Eastern populations 2. Clinical clues include:

• Younger age at presentation (24 vs. 39 years compared to AIH alone)
• Higher alkaline phosphatase (200.7 vs. 111.3 U/L) and bilirubin (2.7 vs. 1 mg/dL) 2
• Adults typically diagnosed with AIH first, then PSC develops years later 2
• Cholestatic biochemistry with suboptimal response to immunosuppression should trigger suspicion 1

Triple Overlap (AIH-PBC-PSC)

While exceptionally rare, triple overlap syndrome has been documented in case reports, particularly in patients with inflammatory bowel disease 3. This represents the extreme end of the autoimmune liver disease spectrum.

When to Suspect Overlap Syndromes

Perform liver biopsy (unless contraindicated) when overlap syndrome is being considered after non-invasive workup including MRCP 1. Specific triggers include:

For PBC Overlap:

• Cholestatic pruritus, cholestatic liver tests, and/or relevant autoantibodies in addition to typical AIH transaminitis 1
• Marked elevation of serum transaminases or IgG in patients with clinical features of PBC 1

For PSC Overlap:

• MRCP should be performed in ALL children with AIH 1, 4
• In adults with otherwise typical AIH who have:
  • Biliary changes on biopsy
  • Cholestatic liver blood tests
  • Pruritus
  • Suboptimal response to immunosuppression
  • Inflammatory bowel disease
  • Subsequent development of any of these features 1

Treatment Approach

Target the predominant component first 1:

When Cholestatic Features Predominate:

• Start with ursodeoxycholic acid (UDCA) 1

When Hepatitic Features Predominate:

• Patients with severe interface hepatitis and/or bridging necrosis on liver biopsy should receive immunosuppression at diagnosis 1

Combination Therapy:

• UDCA plus immunosuppression (prednisolone and azathioprine) provides the best rates of biochemical response with less fibrosis progression 1
• This applies when both components are significant

Critical Management Principles

1. Early review of clinical response to avoid unnecessary long-term treatment 1

2. Regular re-evaluation is essential - the disease phenotype can change over time, with features of one condition becoming more prominent or a second condition developing years after initial diagnosis 1

3. Liver biopsy is key - expert histopathological review is important, and serial biopsies are sometimes needed as the disease evolves 1

4. Exclude IgG4-associated cholangitis - measure serum IgG4 levels in patients with PSC features, as this condition responds to corticosteroids unlike classic PSC 5

Common Pitfalls to Avoid

• Don't diagnose overlap based on single features alone: AMA positivity without bile duct damage, or isolated interface hepatitis in PBC, does not constitute overlap syndrome 2, 1

• Don't miss PSC in children: The distinction between classic PSC and AIH is much less clear in pediatric populations, with up to 50% showing features of both conditions 6

• Don't assume static disease: Features can evolve over months to years, requiring ongoing surveillance and willingness to adjust diagnosis and treatment 1

The rarity of these conditions means no clinical trials exist, so recommendations rely on expert opinion and small case series 1. Given the unpredictable disease course and serious complications, patients require lifelong follow-up 6.